Aprea Therapeutics Reports Early Signs of Activity in APR-1051 Cancer Trial
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced encouraging early clinical data from its ongoing Phase 1 ACESOT-1051 trial evaluating APR-1051, a first-in-class WEE1 kinase inhibitor, in patients with …
Aprea Therapeutics Reports Early Signs of Activity in APR-1051 Cancer Trial Read More